In a baboon graft model of arterial intimal thickening, smooth muscle cells (SMC) have been observed to proliferate underneath an intact monolayer of endothelium and in the absence of platelet adherence. Because platelets are not present and therefore cannot be a major source of growth stimulus, we have proposed that the vascular wall cells in the graft intima express mitogens and regulate SMC proliferation. To test this hypothesis, we assayed the grafts for mitogenic activity and expression of growth factor genes. Segments of healing graft and of normal artery, when perfused ex vivo, released mitogenic activity into the perfusate. The graft released more mitogen than the normal arterial segment, and some of the activity was inhibitable with an antibody to human platelet-derived growth factor (PDGF). In addition, Northern analysis of total RNA demonstrated higher expression of PDGF-A chain mRNA in the graft intima compared to normal artery. PDGF-B chain mRNA was barely detectable in both tissues. PDGF mRNA levels within the graft interstices were not measured. In situ hybridization of 7.5-or 12-wk grafts indicated that some luminal endothelial cells and adjacent intimal SMC contained PDGF-A chain mRNA. By thymidine autoradiography, intimal SMC were observed to be proliferating in the inner third of the intima. These data demonstrate a difference in the pattern of PDGF transcript expression and luminal perfusate activity in graft as compared with control arteries. The association of intimal smooth muscle cell proliferation with intimal PDGF mRNA expression and release of PDGF-like protein supports the hypothesis that factors from cells that have grown into the graft or populated its surface rather than platelets may regulate intimal smooth muscle cell proliferation in this model. (J. Clin. Invest. 1991. 87:406-414.) 
abundance of information regarding growth factors and their secretion by cells in culture, there is limited evidence in vivo that these growth factors play a role in regulating the proliferation of SMC in either the normal artery during growth and development or in diseased vessels with lesions of atherosclerosis.
Studies of human lesions and experimental models of atherosclerosis have suggested a regulatory role for platelet-derived growth factor (PDGF), a potent smooth muscle cell mitogen released by platelets and other arterial cells after activation (1) . PDGF mRNA has been identified by Northern analysis in human atherosclerotic plaques (2) . Increased levels ofPDGF-B mRNA were correlated with increased expression of c-fms (a macrophage-specific marker) and to a lesser extent (-10%) with von Willebrand factor (an endothelial-specific marker) (3) . PDGF-B chain protein has been observed mainly in nonlipid containing macrophages in both human and nonhuman primate lesions of atherosclerosis at all stages of development (4) . In addition, in endarterectomy specimens containing very advanced fibrotic lesions of atherosclerosis, PDGF-B chain message has been demonstrated in endothelial cells by in situ hybridization, whereas PDGF-A chain and the PDGF-3 receptor subunit message appears to be expressed by mesenchymal cells (possibly SMC) (5) . In a rat model ofintimal SMC proliferation, SMC in the media of an injured carotid artery express PDGF-A chain mRNA; at later times SMC migrate into the intima and express mRNA for the beta type of PDGF receptor (6) . In addition to mRNA for PDGF-A chain, cultured SMC derived from human atheroma are capable of producing a PDGF-like protein (7) . Although immunohistochemical techniques have demonstrated pronounced expression of PDGF beta receptor in vascular SMC in atherosclerotic plaques, the receptor is not expressed or is expressed at low levels in normal vessels (8) . None of these studies, however, proves that the PDGF expression or protein present in the lesions are responsible for the proliferation of SMC in vivo.
To evaluate the factors responsible for SMC proliferation and wall thickening in normal and diseased arteries, we have studied a baboon arterial graft model of intimal thickening. In this model (9) , the first event in the healing process is endothelial coverage. After the endothelium has been fully established, SMC appear in the intima and begin to proliferate beneath the endothelium in the absence of platelet adhesion. These observations are consistent with the hypothesis that the vascular wall cells present in the graft intima or within the pores of the graft synthesize growth factors, and that the SMC response to these growth factors is not dependent on factors released from platelets. In this report we show an association between the expression and release of PDGF and SMC proliferation within the intima of healing baboon arterial grafts. Chicago, IL) were placed at each end ofthe graft and arterial segments. They were perfused with the medium described above at 3 ml/h at 370C, and perfusate was collected in serial fractions and frozen at -70'C. During the perfusion, the segments of graft and control artery were immersed in the same medium used for perfusion.
Mitogenesis assay. The mitogenic activity in the perfusates from the graft segments and arterial controls was evaluated by measuring 3H-thymidine incorporation into DNA of human fibroblasts 18-20 h after sample addition as previously described (10) . The Since the level ofmitogenic activity detected in the perfusate was equivalent to 0.5 ng/ml (as compared to a standard curve with purified PDGF-AB), the use of 500 ug/ml of anti-PDGF IgG was necessary to insure neutralization of all dimeric forms (12) . By immunoprecipitation, neutralization of mitogenesis, and ELISA, we could not detect cross-reactivity with acidic and basic fibroblast growth factor, epidermal growth factor, transforming growth factor a, transforming growth factor fl, or insulin-like growth factor I. Both the anti-PDGF IgG and the nonimmune IgG were purified from plasma and were therefore devoid of platelet growth factors and had no endogenous mitogenic activity at the doses used in these experiments.
Assaysfor plateletfactor 4 (PF4), beta-thromboglobulin (beta-TG), and lactate dehydrogenase (LDH). Samples ofperfusate collected from control arteries and from grafts were examined by radioimmunoassay for content of PF4 (Abbot Laboratories, No. Chicago, IL) and beta-TG (Amersham Corp., Arlington Heights, IL). A chromogenic activity assay (Macomb, Romeo, MI) was used to determine the LDH content in the perfusates from both graft and artery.
RNA extraction and Northern analysis. The graft was quickly removed, rinsed with 0.9% NaCl, and cut open. The intima was stripped from the graft matrix and immediately frozen in liquid nitrogen. Three grafts were analyzed at each time point. The thoracic aorta was also removed, rinsed, and immediately frozen in liquid nitrogen.
The frozen intima and aortic tissue was ground to a fine powder with a mortar and pestle cooled with liquid N2 and then homogenized with a polytron in buffer containing 5 M guanidine isothiocyanate, 10 mM EDTA, 50 mM Tris-HCJ, pH 7.5, and 8% (vol/vol) f-mercaptoethanol (13). RNA was not extracted from graft matrix. All reagents were molecular biology grade. Total RNA was selectively precipitated by the addition of lithium chloride according to the procedure ofCathala et al. (12) . 10 gg of total RNA sample was electrophoresed in 1% agarose and transferred to nylon membranes (Zetaprobe; Bio-Rad Laboratories, Richmond, CA) for Northern analysis (14) . Human PDGF-A (1.3-kb Eco RI human cDNA fragment) (15) or PDGF-B (1.2-kb PST I fragment of v-sis) (16) cDNA probe labeled with 32P by nick translation (17) was added to the hybridization solution (50% formamide in 0.14 M sodium phosphate buffer, pH 7.2, containing 0.25 M NaCl/7.0% SDS/1 mM EDTA/10% polyethylene glycol) at 2 X 106 cpm/ml. Hybridization was performed at 42°C for 20-24 h. After hybridization, the blots were washed in 2 X SSC/0. 1% SDS at room temperature for 30 min, followed by 0.1 X SSC/0.1% SDS at 65°C for 10-15 min. Signals were detected by autoradiography and quantitated by densitometry.
In situ hybridization. Probes specific to human PDGF A chain (14) or PDGF B chain (18) were labeled by transcription (19) using 35S-labeled UTP (specific activity, 1,200 Ci/mmol; Amersham Corp., Arlington, IL). Full-length antisense transcripts were used for hybridization. The final specific activity of these probes was 300 Ci/mmol.
In situ hybridization was performed as previously described (5, 20) . Briefly, cryosections were pretreated with paraformaldehyde, proteinase K (Sigma Chemical Co., St. Louis, MO), and prehybridized in 100
Al hybridization buffer (50% formamide, 0.3 M NaCl, 20 mM Tris, pH 8 .0, 5 mM EDTA, 0.02% polyvinylpyrrolidine, 0.02% Ficoll, 0.02% BSA, 10% dextran sulfate, and 10 mM dithiothreitol) at 42°C. Serial sections were hybridized by addition of 600,000 CPMs of 3"S-labeled PDGF-A or -B chain riboprobes and incubation overnight at 55°C. After hybridization, the sections were washed with 2 X SSC (1 X SSC = 150 mM NaCl, 15 mM Na citrate, pH 7.0) with 10 mM f3-mercaptoethanol and 1 mM EDTA, treated with RNase (Sigma Chemical Co.), followed by a high-stringency wash in 0.1 x SSC with 10 mM fl-mercaptoethanol and 1 mM EDTA, at 55°C. The slides were then washed in SSC without ,B-mercaptoethanol, dehydrated in graded alcohols containing 0.3 M NH4Ac, dried, coated with NTB2 nuclear track emulsion (Eastman Kodak Co., Rochester, NY), and exposed in the dark at 4°C for 4-12 weeks. After development, the sections were counterstained with hematoxylin and eosin to aid in cell identification.
Immunohistochemistry. Monoclonal antibodies were used, as described previously, to identify cell types in the graft (21). Paraffin-embedded tissue sections were stained using the biotin-avidin-peroxidase technique with diaminobenzidene-NiCI2 as the chromogen (22). Endothelial cells were identified by punctate staining with a polyclonal rabbit antibody to human factor VIII-related antigen (Dako Corp., Santa Barbara, CA) (23) . SMC stained with a mouse monoclonal antibody (HHF 35) against human smooth muscle-specific actin isotypes (24), and macrophages were identified with a mouse monoclonal antibody to human macrophages (HAM 56) (24a); these monoclonal antibodies were a gift of Dr. Allen Gown.
Thymidine autoradiography. Three animals were killed I mo after receiving three doses oftritiated thymidine (0.5 mCi/kg per dose) (New England Nuclear, Boston, MA) by intramusclar injection (9) . One-half hour before fixation, heparin (3,000 U) and Evans blue (50 mg/kg) were given by intravenous injection. The animals were killed by anesthetic overdose, and their arteries were fixed by perfusion with 2.5% glutaraldehyde in 0.1 mM phosphate buffer, pH 7.4, at 100 mmHg. The grafts were excised, further fixed by immersion, and then washed extensively. Rings of graft were embedded in paraffin and cross-sectioned. Unstained deparaffinized histologic sections were dipped in Kodak NTB 2 emulsion, allowed to dry, and kept at 4VC in light-tight boxes for 2 wk. Slides were developed in Kodak 0-19 developer and fixed. After staining with hematoxylin, the autoradiograms were evaluated at high power ( 100X) to determine the distribution oflabeled SMC in the intima.
Results
The time course ofgraft healing. The morphologic and autoradiographic characteristics of graft healing were reported previously (9, 21, 25) . Briefly, after implantation of the grafts, the surface is covered by a layer of thrombus. Subsequently, capillaries and microvessels from the surrounding granulation tissue penetrate the graft matrix and provide multiple sources of endothelium and SMC to cover the luminal surface. The Ex vivo perfusate contains mitogenic activity. Grafts were excised at various times after placement and perfused ex vivo. Mitogenic activity for human fibroblasts was detected in both graft and artery perfusates. The release of mitogenic activity into the perfusate was evaluated at several points in time during the perfusion ex vivo. Initial collections (at 2-h intervals for the first 6 h) contained more mitogenic activity than those obtained at subsequent times (8-22 h). The level of mitogenic activity, however, was constant in collections evaluated between 8 and 22 h (Fig. 3) .
Evidence that the mitogenic activity in the perfusate is not derivedfrom necrotic cells or adherent platelets. We were concerned that the release of mitogenic activity into the perfusate might be the result of cell injury or death from surgical graft removal and perfusion. However, scanning electron microscopy demonstrated that the endothelial lining was still present on the luminal surface of the segments ofgraft and artery after 1200- Figure 3 . No adherent platelets were observed on the luminal surface ofthe graft and arterial segments. However, there remained the possibility that the initial measurement of a high level of mitogenic activity in the perfusate might be due to adherent thrombus not successfully rinsed free from the grafts. To investigate this, we measured beta-TG and PF4 levels in the perfusate, because these molecules are constituents of platelet granules and are liberated during the release reaction (Table I) . As a positive control, some grafts were removed 1 h after placement. These grafts exhibited only thrombus on the luminal surface. Perfusates of these 1-h grafts had elevated levels of both PF4 and beta-TG in collections obtained between 0 and 8 h and 8 and 24 h of perfusion ex vivo. For grafts and arteries removed at 2 wk and after, some of the perfusate fractions collected between 0 and 4 h of perfusion contained detectable PF4 and beta-TG levels, suggesting that there might be slight contamination with platelet products. However, PF4 and beta-TG were not present in perfusate fractions collected from either graft or artery between 8 and 22 h of perfusion (Table I) . Therefore, to limit evaluation to perfusates that contained no detectable levels of platelet products, all comparisons of mitogenic activity were performed on perfusate fractions collected between 8 and 22 h of perfusion ex vivo.
Perfusatesfrom grafts contain more mitogenic activity than perfusates from arteries. Measurements were made of mitogenic activity in the perfusate fractions collected (8-22 h) from all the pairs ofgrafts and arteries. The mitogenic activity in the perfusates was normalized to luminal surface area and expressed as a ratio (graft/artery). For each time period of graft healing, this ratio was > 1.0, indicating that there was a significantly higher level of mitogenic activity in the graft perfusates than in the control artery perfusates ( Fig. 4 ; P < 0.05). Part ofthe mitogenic activity ofthe graft perfusate is antigenically related to PDGF. A polyclonal anti-PDGF neutralizing antibody was used to evaluate the contribution of PDGFlike protein to the mitogenic activity of the graft perfusates. Compared to nonimmune IgG, anti-PDGF IgG significantly decreased the mitogenic activity of the graft perfusates. The decrease in mitogenic activity was -40-45%. The presence of PDGF was confirmed by PDGF radioreceptor assay (data not shown) (26). However, due to the small amounts ofPDGF-like protein present in the perfusates, analysis of the levels of PDGF-like protein by radioreceptor assay would have required pooling samples from more than one animal. PDGF-like protein was demonstrated by neutralization of mitogenic activity in perfusates of2-wk and 1-mo grafts (Table II) . Although there was variability between experiments, PDGF-like protein accounted for a significant portion of the mitogenic activity of each graft perfusate in all of the samples.
Expression ofPDGF mRNA bygraft intimal cells. To determine whether PDGF transcript levels were altered in the grafts, Northern analysis was performed on total cellular RNA extracted from the control arteries and the intimas of the grafts wk were hybridized to PDGF-A and -B chain specific riboprobes. In the 12-wk graft we were able to detect PDGF-A chain mRNA predominantly in the lumenal endothelial cells (Fig. 6 , a and c) as well as in occasional intimal SMC (Fig. 6 c) . Serial sections of these grafts suggested a weak PDGF-B chain hybridization to the luminal endothelium (Fig. 6, b and d) but not to the intimal SMC. Similar results were seen in the 7.5 wk graft with detection ofPDGF-A chain mRNA in lumenal endothelial cells and in SMC throughout the graft intima (Fig. 6 e) . However, we failed to detect any PDGF-B chain mRNA hybridization at this time (Fig. 6f) . At both times, cells containing PDGF-A and -B chain mRNA were detected within the interstices of the porous graft material but were not conclusively identified (data not shown).
Discussion
In our baboon model of arterial intimal thickening, SMC proliferate beneath an intact endothelium in the absence ofadherent platelets. This observation suggests that growth factors for the SMC may originate in the cells of the graft rather than in platelets. This concept is supported by our observationsdemonstrating in an ex vivo perfusion system that a healing graft releases into the luminal perfusate more mitogenic activity than a normal arterial segment. This mitogenic activity is partially inhibitable by a monospecific anti-PDGF antibody, and Northern analysis of mRNA and in situ hybridization studies show elevated expression of PDGF-A in the graft intima as compared with normal artery. When these results are considered together with our earlier observation, they suggest that the SMC proliferation in this system in vivo is associated with increased expression of PDGF A chain mRNA in the intimal cells and the presence of PDGF-like protein.
PDGF as a regulator ofSMC growth. PDGF has been implicated in the regulation of cellular proliferation in vitro and in vivo. This protein growth factor is released in at least three forms, which are the dimeric combinations of two distinct but homologous chains, termed A and B chain. located on different chromosomes (26). PDGF, originally found in platelets, is also secreted in vitro by many different cell types, including endothelial cells, smooth muscle cells, monocyte/macrophages, and numerous transformed cell lines (1, 27) .
The expression and secretion of PDGF by normal diploid cells appears to be tightly regulated. For example, bovine aortic or human umbilical vein endothelial cells stripped from blood vessels contain only 10% and 1.3%, respectively, as much Bchain transcript as the same cells in monolayer culture (28) . When endothelium switches from a monolayer to tubelike structures in culture it alters its expression of A-and B-chain mRNA (29) (30) (31) . Transient expression of PDGF is induced in response to cell activation by coagulation factors and by cytokines, as well as by variations in cell substrate (1, 12, 27) .
The response of SMC to PDGF is affected not only by the abundance of the growth factor but also by the regulated expression of PDGF receptors. For example, it has been demonstrated that there are two different receptor subunits that can combine to create different receptor phenotypes for PDGF (32) (33) (34) (35) . The alpha-subunit can bind either the A or B chain of PDGF, whereas the beta-subunit can bind only the B chain. Therefore, the response of a given cell depends both on the isoform ofPDGF present and the total number and proportion of alpha-and beta-subunits of the receptor present on the cell surface (26, 35) . To establish that PDGF is indeed the endogenous regulator of intimal SMC proliferation, pharmacological means to block its activity and measurements ofreceptor function in vivo will be required.
Sources ofmitogenic activity. The neointima is largely composed of SMC and is covered with a luminal monolayer of endothelium. Macrophages are rarely present in the intima but reside in large numbers within the interstices ofthe porous graft material. Therefore, ifthe cells in the graft are the source ofthe growth factor that drives the SMC proliferation, then endothelium and SMC appear to be the most likely source because the proliferating SMC are mostly located near the luminal surface. Both cell types in vitro have been shown to secrete growth factors, including PDGF, that are capable of stimulating SMC proliferation (1, 27) .
The SMC that are proliferating in the intima ofthe healing grafts are concentrated in the region just beneath the endothelium, and the in situ hybridization studies demonstrate that endothelial cells and adjacent intimal SMC are expressing PDGF A chain mRNA. From these results, it appears that these two cell types are the major source ofPDGF which might be responsible for the growth ofthe underlying SMC. The endothelial cells might synthesize and release factors (36) (37) (38) , or alternatively, they might interact with the SMC in such a way as to stimulate the SMC to produce their own mitogen. Coculture and conditioned medium experiments in vitro have provided support for these kinds of interactions (39, 40) .
The mitogenic activity detected in the lumen of the grafts might be only a small fraction of the mitogens available to the intimal SMC. If endothelium and SMC are the sources of PDGF in this model, it seems more likely that they should secrete the growth factor into the matrix than into the lumen. Cultured endothelial cells have been shown to secrete PDGF vectorially into the abluminal, basal compartment (41). The mitogenic activity detected in the graft perfusates might represent activity leached out of the graft matrix. At present we do not have the reagents to determine the dimeric form of PDGF and to localize the protein within the intima.
If the endothelial cell is the source of the mitogen for the SMC, then there must be a difference between the endothelial cells of the graft and the endothelial cells of the artery to account for the differences in expression of mitogenic activity. Scanning microscopy shows that the endothelial cells in the graft are larger than those found in the artery (25) . The graft endothelial cells are also proliferating at a higher rate than arterial endothelial cells (9) , presumably because of some form of injury (42, 43) . Endothelial cells turning over at a relatively high rate might be in a different functional state, including production of a mitogen for SMC or mediators capable of inducing the production of growth factors by SMC themselves. Several stimuli have been shown to affect the production of mitogens by endothelial cells in vitro (43) (44) (45) (46) (47) (48) .
SMC are present in both the artery and the graft intima. If they are in part regulating their own proliferative state (6, 7, 14, (49) (50) (51) (56) . The mitogenic activity detected in the graft perfusate reflects the response ofthe test cells to the combination ofstimulatory and inhibitory factors in the perfusate. The presence of inhibitory substances in the perfusate, and in the vessel wall, might also be important determinants of the extent and location of the intimal SMC proliferation in vivo. For example, heparan sulfate secreted by endothelium and SMC inhibits SMC growth in vitro and might be an inhibitor of SMC in vivo (57, 58) . Latent transforming growth factor-beta activated by endothelium-pericyte interactions has been shown to be an inhibitor of cellular proliferation in vitro (40) and might also be active in vivo.
Our studies suggest that PDGF may be important in the regulation of the SMC proliferation observed in the graft intima. Although we have not identified the specific factors that induce increased PDGF A-chain gene expression in the graft intima, we have observed a difference in the pattern of PDGF A-chain expression and luminal perfusate mitogenic activity in the graft as compared to the control artery. In this organized vascular tissue, the association of intimal SMC proliferation with the presence ofintimal PDGF A-chain mRNA expression and release of PDGF-like protein supports the concept that factors from the cells in the intima rather than platelets may regulate intimal SMC proliferation.
